Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04065750

Acronym

BactHub

Enrollment

45000

Registered

2019-08-22

Start date

2023-11-13

Completion date

2023-12-31

Last updated

2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia

Keywords

bacteremia, resistant bacteria, antibiotic

Brief summary

The primary objective of the study is to identify the risk factors of community-acquired bacteremia to resistant bacteria. As the secondary objectives, the study aims * to describe the episodes of epidemiology of bacteremia (community-acquired and nosocomial) with inpatient patients in APHP. * to research a potential correlation between the incidence of community-acquired bacteremia of studied germs and the evolution of antibiotics consumption in general population in Île de France region. * to distinguish three categories of community-acquired bacteremia: real community-acquired infections, infections beginning in community (patients discharged a community care center within 3 months), the nosocomial infections (patients discharged a health center within 7 jours). Describe the epidemiology of resistance and the differential impact of individual exposure to antibiotics in these three categories. * to identify, according to pathogens, a temporal threshold from which a prior stay in a health center or HAD would impact on the occurrence of a community-acquired bacteremia with a resistant bacterium. * to describe prospectively for follow-up of 1 year for hospitalized patients for a community-acquired or nosocomial bacteremia: mortality at one month and 3 months, re-hospitalization for an infectious episode and isolated bacteria during this later episode.

Detailed description

The investigators will study in particularly individual exposure to antibiotics: exposure in 3 months ou in 12 months, cumulative exposure, hospital- and community-acquired exposure, etc.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For bacteraemia cohort: All inpatient patients in a hospital of APHP between January 2010 and december 2018 with at least one haemoculture positive. * presence of at least a bacteremia as primary diagnosis, related diagnosis and associated diagnosis: A40 (streptococcus), A41 (staphylococcus, BGN, anaerobes, others), A32.7 (Listeria), A39.4 (meningocoele), A42.7 (Actinomyces), A02.1 (Salmonella), A54.8 (gonocoque), A48.0 (Clostridium). * and/or in biological data presence of at least a haemoculture positive to Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Acinetobacter Baumannii, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Pseudomonas aeruginosa, Streptococcus sp., Salmonella sp., Clostridium difficile. For control cohort: Patients cared in a hospital of APHP between 2010 and 2018 without infection. - Patients without infection of CIM-10 bacteraemia as primary diagnosis, related diagnosis and associated diagnosis, without haemoculture positive in microbiology.

Exclusion criteria

\- Patients aged \< 18 years

Design outcomes

Primary

Measure	Time frame
Incidence of bacteraemia	through study completion, an average of 3 months

Secondary

Measure	Time frame	Description
Mortality	at 30 day and 90 day	Events of death will be recorded, the mortality rate will be calculated for 30 day and 90 day.
Rehospitalization	12 months	The rate of 12 months unplanned rehospitalization for infection by the same biological pathogenes was recorded.

Contacts

Primary ContactLaurence Watier, PhD

Laurence.watier@inserm.fr+33 (0) 1 45 68 83 01

Backup ContactSalam Abbara, MD, PhD

Outcome results